15 articles about Boston Pharma
Boston Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting New Phase 2 Clinical Data from BOS-580 NASH Program at EASL 2023
Boston Pharmaceuticals today announced that new results from its ongoing Phase 2a study evaluating BOS-580 for the treatment of non-alcoholic steatohepatitis (NASH) were accepted as a late-breaking poster presentation at the European Association for the Study of the Liver International Liver Congress, June 21-24 in Vienna, Austria.
Boston Pharmaceuticals Appoints Dr. Sophie Kornowski as Chair of its Board of Directors and Acting Chief Executive
Boston Pharmaceuticals, a clinical stage biopharmaceutical company, today announced the appointment of Dr. Sophie Kornowski as Chair of its Board of Directors and Acting Chief Executive Officer, effective immediately.
Boston Pharmaceuticals Doses First Patient in Phase 2a Clinical Trial of BOS-580 for NASH
Boston Pharmaceuticals announced administration of BOS-580 to the first patient in a Phase 2a clinical trial in individuals with nonalcoholic fatty liver disease and/or nonalcoholic steatohepatitis.
Boston Pharmaceuticals Enters into Unique Multi-Year Out-License and Option Agreement with GSK for the Advancement of Multiple Pre-Phase 2 Programs
Boston Pharmaceuticals announced today a pioneering three-year out-license and option agreement with GlaxoSmithKline PLC (LSE/NYSE: GSK). Boston Pharmaceuticals will become a preferred GSK partner for select pre-phase 2 programs. This new agreement builds on the relationship established in 2018 with Boston Pharmaceutic
Boston Pharmaceuticals licensed the drug candidate BOS-580, an injectable, genetically engineered variant of human FGF21.
Boston Pharmaceuticals Named One of the 2020 Best Workplaces in Health Care & Biopharma by Great Place to Work® and Fortune
Boston Pharmaceuticals is honored to have been named one of the top ten Health Care and Biopharma companies on Fortune’s 2020 Best Workplaces ranking.
Akaal Pharma Pty Ltd Announces Licensing Agreement for its First-in-Class, Topical Spingosine-1-Phosphate-1 (S1P1) Receptor Modulator for Atopic Dermatitis and Psoriasis
Akaal Pharma Pty Limited today announced that it has entered into a licensing agreement for Akaal Pharma’s First-in-Class, topical Spingosine-1-Phosphate-1 (S1P1) modulator, AKP-11, with Boston Pharmaceuticals, Inc. (Boston Pharmaceuticals).
According to Jay Bradner, president of the Novartis Institutes for Biomedical Research, the company is cutting its drug programs from 430 to 340. One of the big areas the company is abandoning is infectious diseases. The decision is a result of a strategic review by Vasant (Vas) Narasimhan, the c...
Boston Pharma went on a buying binge, licensing a slew of compounds from GlaxoSmithKline and Novartis in two separate deals.
Boston Pharmaceuticals Appoints Dr. Peter Ho as Chief Medical Officer
Dr. Ho joins Boston Pharmaceuticals from Epizyme, where as Chief Medical Officer he led the company’s clinical development, translational medicine and regulatory affairs functions.
Boston Pharma Appoints Dr. Peter Ho as CMO
Dr. Ho joins Boston Pharma from Epizyme, where as CMO he led the company's clinical development, translational medicine and regulatory affairs functions.
Daiichi Sankyo Enters Worldwide Licensing Agreement With Boston Pharma For A Highly Selective RET Inhibitor For Solid Tumors
Boston Pharma Appoints Ian Sanderson As CFO
Sanofi's Ex-Chief Viehbacher Launches Boston Pharma With $600 Million
Boston Pharma Appoints Santiago Arroyo, M.D., Ph.D., As Chief Medical Officer And Constantine Chinoporos, As Chief Business Officer